BioMimetic Therapeutics Earnings Conference Call (Q2 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Aug 10 Calls Today's Calls

Call Details BioMimetic Therapeutics Earnings Conference Call (Q2 2009) Mon, Aug 10, 2009, 4:30 pm Eastern Listen to the archived event audio About BioMimetic Therapeutics (NasdaqGM:BMTI) BioMimetic Therapeutics, Inc. develops and commercializes regenerative protein therapeutic-device combination products. Its products are primarily used for bone and tissue regeneration for the repair and healing of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage within orthopedic, spine, and sports injury applications. The company’s lead orthopedic product candidate includes Augment Bone Graft, for treating bone defects and injuries. It also has pre-clinical products, which include Augment Injectable Bone Graft for closed non-surgical fracture treatment; TBD for spine fusion; and Augment C for cartilage repair and Augment LT for ligament and tendon repair. The company was formerly known as BioMimetic Pharmaceuticals, Inc. and changed its name to BioMimetic Therapeutics, Inc. in July 2005. BioMimetic Therapeutics, Inc. was founded in 1999 and is headquartered in Franklin, Tennessee. More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings